Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology
The Society describes its “Best of ASH” selections, chosen from among the thousands of meeting abstracts, as “the biggest breakthroughs from the meeting's scientific presentations.”
“Having both the MEDALIST and BELIEVE trials included in the Best of ASH
session at the close of the annual meeting is extraordinarily
The full titles of the trials highlighted during the Best of ASH session are as follows:
‘MEDALIST’ trial presentation
Title: The MEDALIST Trial: Results of a Phase 3, Randomized,
Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia
in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic
Syndromes (MDS) with Ring Sideroblasts (RS) who Require Red Blood Cell
‘BELIEVE’ trial presentation
Title: The BELIEVE Trial: Results of a Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Study of Luspatercept in Adults Who
Require Regular Red Blood Cell (
Luspatercept is an investigational therapy that is not approved for any
use in any country.
Luspatercept is a first-in-class erythroid maturation agent (EMA) that
is believed to regulate late-stage red blood cell maturation. Acceleron
Patients with lower-risk MDS suffer from insufficient production of red blood cells, resulting in chronic anemia that can lead to debilitating fatigue, diminished quality of life and increased mortality. Many patients with lower-risk MDS-related chronic anemia require frequent red blood cell transfusions.
Beta-thalassemia is caused by a genetic defect in the production of hemoglobin, a protein that carries oxygen to red blood cells throughout the body. Patients suffer from severe, chronic anemia and often experience fatigue, organ enlargement, and bone complications. Patients require lifelong therapy that includes frequent red blood cell transfusions and treatment of the consequent iron overload.
Acceleron is a
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner,
This press release contains forward-looking statements about Acceleron’s strategy, future plans and prospects, including statements regarding the development of Acceleron’s compounds, the timeline for clinical development and regulatory approval of Acceleron’s compounds and the expected timing for reporting of data from ongoing clinical trials. The words "anticipate," "believe," "could," "estimate," "expect," “goal,” "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results could differ materially from those included in the
forward-looking statements due to various risks and uncertainties,
including, but not limited to, that preclinical testing of Acceleron’s
compounds and data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that the
development of Acceleron’s compounds will take longer and/or cost more
than planned, that Acceleron or its collaboration partner,
The forward-looking statements contained in this press release are based on management’s current views, plans, estimates, assumptions and projections with respect to future events, and Acceleron does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Acceleron Pharma Inc.
Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
Candice Ellis, (617) 649-9226
Manager, Investor Relations
Matt Fearer, (617) 301-9557
Director, Corporate Communications